Quantcast

Latest CSL Behring Stories

2014-04-16 16:26:40

LONDON, April 16, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:PharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022http://www.reportbuyer.com/pharma_healthcare/diseases/pharmapoint_hemophilia_us_drug_forecast_market_analysis_2022.htmlPharmaPoint: Hemophilia A and B - US Drug Forecast and Market Analysis to 2022SummaryThe competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of...

2014-04-16 08:32:37

6.9 million people have a bleeding disorder. 75 percent of them don't know it. MONTREAL, April 16, 2014 /PRNewswire/ -- Every year on April 17, World Hemophilia Day is observed around the world to increase awareness of hemophilia and other inherited bleeding disorders. In 2014, World Hemophilia Day's theme will encourage the younger generation of the global bleeding disorders community to "Speak out. Create change." "World Hemophilia Day is part of our critical effort to aid in...

2014-03-24 12:25:01

KING OF PRUSSIA, Pa., March 24, 2014 /PRNewswire/ -- Navigating the complexities of the Affordable Healthcare Act (ACA) can be challenging, particularly where patients with chronic medical disorders such as hemophilia and von Willebrand disease are concerned. CSL Behring is awarding a Local Empowerment for Advocacy Development (LEAD) grant to help bleeding disorder patients develop a clearer understanding of ACA and potential areas of concern....

2014-03-01 12:20:36

Analysis also reveals decrease in emergency room visits and hospitalizations SAN DIEGO, March 1, 2014 /PRNewswire/ -- Findings announced by CSL Behring today show that current hereditary angioedema (HAE) treatment options, such as C1 Esterase Inhibitor (C1-INH) concentrate, are allowing for greater patient satisfaction, higher rates of home treatment and a decrease in the number of hospitalizations and visits to the emergency room. HAE is a rare, potentially fatal swelling disorder...

2014-02-28 04:20:20

DUBLIN, Feb. 28, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/rfcfm5/china_human ) has announced the addition of the "Concise Analysis of the Chinese Human Albumin Industry" report to their offering. (Logo:http://photos.prnewswire.com/prnh/20130307/600769) 'Concise Analysis of the Chinese Human Albumin Industry' is a professional and in-depth research report on the human albumin industry in China. The report provides basic information on the...

2014-02-27 12:27:13

bioCSL Inc. initiates 2014-15 season pre-booking for AFLURIA® (Influenza Vaccine) KING OF PRUSSIA, Pa., Feb. 27, 2014 /PRNewswire/ -- CSL Biotherapies Inc. announced today it has changed its name to bioCSL Inc., effective February 21, 2014. This change is pursuant to the Australian, New Zealand and German renaming of the company, which occurred one year ago. In September 2013, bioCSL was the first United States supplier to complete its 2013-14 seasonal influenza vaccine delivery...

2014-02-25 12:27:56

DUBLIN, Feb. 25, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/ncdhtt/intravenous ) has announced the addition of the "Concise Analysis of the International Intravenous Immunoglobulin (IVIg) Market" report to their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769) This report analyzes the worldwide markets for Intravenous Immunoglobulin (IVIg) in US$ Million. The report provides separate comprehensive analytics for the US, Canada,...

2014-02-20 08:32:30

Year-round charitable giving includes over $700k to United Way KING OF PRUSSIA, Pa., Feb. 20, 2014 /PRNewswire/ -- You can tell a lot about a company and its employees by the way they give back to the community. CSL Behring, its subsidiary, CSL Plasma and their employees do just that, year-round, supporting a wide range of organizations that provide services to people in need. http://photos.prnewswire.com/prnvar/20100914/PH63692LOGO The annual United Way campaign is the company's single...

2014-02-20 08:32:25

International study by CSL Behring is world's first placebo-controlled phase III trial to examine subcutaneous administration of C1-INH for use in treating rare, sometimes life-threatening, condition KING OF PRUSSIA, Pa., Feb. 20, 2014 /PRNewswire/ -- CSL Behring today announced it has enrolled the first patient in COMPACT, an international phase III study of a volume-reduced, subcutaneous formulation of C1-esterase inhibitor (C1-INH) concentrate in patients with frequent hereditary...


Word of the Day
barghest
  • A goblin in English folklore, often appearing in the shape of a large dog and believed to portend imminent death or misfortune.
  • A ghost, wraith, hobgoblin, elf, or spirit.
The origin of 'barghest' is not known, but it may be from perhaps burh-ghest, town-ghost, or German Berg-geist (mountain spirit) or Bär-geist (bear-spirit).
Related